Early F-18-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab

Chen, AP; Mokrane, FZ; Schwartz, LH; Morschhauser, F; Stamatoullas, A; de Colella, JMS; Vercellino, L; Casasnovas, O; Chauchet, A; Delmer, A; Nicolas-Virelizier, E; Ghesquieres, H; Moles-Moreau, MP; Schmitt, A; Dulery, R; Bouabdallah, K; Borel, C; Touati, M; Deau-Fischer, B; Peyrade, F; Seban, RD; Manson, G; Armand, P; Houot, R; Dercle, L

Dercle, L (corresponding author), Columbia Univ, New York Presbyterian Hosp, Dept Radiol, Med Ctr, 68 Bradhurst Ave, New York, NY 10039 USA.

JOURNAL OF NUCLEAR MEDICINE, 2020; 61 (5): 649

Abstract

Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, are associated with high response rates in p......

Full Text Link